![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1589016
¼¼°èÀÇ ÀǾàǰ ºÐ¼® ½ÃÇè ¾Æ¿ô¼Ò½Ì ½ÃÀåPharmaceutical Analytical Testing Outsourcing |
Á¦¾à ºÐ¼® ½ÃÇè ¾Æ¿ô¼Ò½Ì ¼¼°è ½ÃÀåÀº 2030³â±îÁö 163¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î Àü¸Á
2023³â 103¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ÀǾàǰ ºÐ¼® ½ÃÇè ¾Æ¿ô¼Ò½Ì ¼¼°è ½ÃÀåÀº 2023³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 6.8% ¼ºÀåÇÏ¿© 2030³â¿¡´Â 163¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ º¸°í¼¿¡¼ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¹ÙÀÌ¿À ºÐ¼® Å×½ºÆ® ¼ºñ½º´Â CAGR 8.0%¸¦ ±â·ÏÇÏ¿© ºÐ¼® ±â°£ Á¾·á ½ÃÁ¡¿¡ 64¾ï ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ºÐ¼® ±â°£ µ¿¾È ºÐ¼®¹ý °³¹ß ¹× °ËÁõ ¼ºñ½º ºÐ¾ßÀÇ ¼ºÀå·üÀº CAGR 6.8%·Î ÃßÁ¤µË´Ï´Ù.
¹Ì±¹ ½ÃÀå 28¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 6.2%·Î ¼ºÀå Àü¸Á
¹Ì±¹ÀÇ ÀǾàǰ ºÐ¼® ½ÃÇè ¾Æ¿ô¼Ò½Ì ½ÃÀåÀº 2023³â 28¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2023-2030³â ºÐ¼® ±â°£ µ¿¾È ¿¬Æò±Õ 6.2%ÀÇ ¼ºÀå·üÀ» º¸À̸ç 2030³â¿¡´Â 25¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ª ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ µ¿¾È °¢°¢ 6.5%¿Í 5.2%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·´¿¡¼´Â µ¶ÀÏÀÌ ¿¬Æò±Õ 5.3%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¼¼°è ÀǾàǰ ºÐ¼® ½ÃÇè ¾Æ¿ô¼Ò½Ì ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃßÁø ¿äÀÎ ¿ä¾à
ÀǾàǰ ºÐ¼® ½ÃÇè ¾Æ¿ô¼Ò½Ì »ê¾÷Àº ¾î¶»°Ô ¹ßÀüÇØ ¿ÔÀ»±î?
Á¦¾à ºÐ¼® ½ÃÇè ¾Æ¿ô¼Ò½Ì »ê¾÷Àº Áö³ 20³â µ¿¾È Å©°Ô ¹ßÀüÇØ ¿Ô½À´Ï´Ù. ±× ÁÖ¿ä ¿äÀÎÀº ÀǾàǰ °³¹ßÀÇ º¹À⼺, ±ÔÁ¦ ´ç±¹ÀÇ °¨½Ã, ºñ¿ë È¿À²ÈÀÇ Çʿ伺ÀÔ´Ï´Ù. ±âÁ¸¿¡´Â Á¦¾àȸ»ç°¡ ´ëºÎºÐÀÇ ºÐ¼®½ÃÇèÀ» ÀÚüÀûÀ¸·Î ¼öÇàÇÏ¿© ¿¬±¸°³¹ßºÎÅÍ ½ÃÀ尳ô±îÁö ÀǾàǰ °³¹ßÀÇ ¸ðµç ´Ü°è¸¦ °ü¸®Çß½À´Ï´Ù. ±×·¯³ª ÀǾàǰ ÆÄÀÌÇÁ¶óÀÎÀÌ º¹ÀâÇØÁö°í ±ÔÁ¦ ´ç±¹ÀÇ ¿ä±¸»çÇ×ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¸¹Àº ±â¾÷µéÀÌ ÀÌ·¯ÇÑ Àü¹® ½ÃÇè ±â´ÉÀ» ¿ÜºÎ ÆÄÆ®³Ê¿¡°Ô ¾Æ¿ô¼Ò½ÌÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È¸¦ ÅëÇØ Á¦¾à»çµéÀº ½Å¾à °³¹ß ¹× »ó¾÷È¿Í °°Àº ÇÙ½É ¿ª·®¿¡ ÁýÁßÇÒ ¼ö ÀÖ°Ô µÇ¾úÀ¸¸ç, ºÐ¼® ½ÃÇè ¼ºñ½º¿¡¼´Â CROÀÇ Àü¹®¼ºÀ» Ȱ¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.
¿À´Ã³¯ ¾Æ¿ô¼Ò½ÌÀº ÀǾàǰ ¿¬±¸°³¹ß(R&D)¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù. ÀǾàǰ ºÐ¼® ½ÃÇè¿¡´Â ¿ø·á ½ÃÇè, ½ÃÇè¹ý °³¹ß, ¾ÈÁ¤¼º ½ÃÇè, »ý¹°ÇÐÀû ºÐ¼® ¼ºñ½º, Á¦Ç° Ãâ½Ã ½ÃÇè µî ´Ù¾çÇÑ ¼ºñ½º°¡ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ ¼ºñ½º¸¦ ¾Æ¿ô¼Ò½ÌÇÔÀ¸·Î½á Á¦¾à»çµéÀº ¸·´ëÇÑ ÀÚº» ÅõÀÚ ¾øÀ̵µ ÃÖ÷´Ü ±â¼ú, ÷´Ü Àåºñ, ±ÔÁ¦ °ü·Ã Àü¹® Áö½ÄÀ» Ȱ¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ±× °á°ú, ¾Æ¿ô¼Ò½Ì ½ÃÀåÀº ºñ¾àÀûÀÎ ¼ºÀåÀ» ÀÌ·ç¾úÀ¸¸ç, CRO´Â ¼Ò±Ô¸ð »ý¸í°øÇÐ ±â¾÷ºÎÅÍ ´ëÇü Á¦¾à»ç±îÁö ´Ù¾çÇÑ ¼ö¿ä¸¦ ÃæÁ·½Ãų ¼ö ÀÖ´Â Á¾ÇÕÀûÀÎ ¼ºñ½º¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù.
±â¼úÀÇ ¹ßÀüÀº ¾î¶»°Ô Á¦¾à ºÐ¼® ½ÃÇè ¾Æ¿ô¼Ò½Ì ½ÃÀåÀ» Çü¼ºÇϰí Àִ°¡?
±â¼úÀÇ ¹ßÀüÀº °Ë»ç ÇÁ·Î¼¼½ºÀÇ Á¤È®¼º, È¿À²¼º ¹× ¼Óµµ¸¦ Çâ»ó½ÃÅ´À¸·Î½á Á¦¾à ºÐ¼® Å×½ºÆ® ¾Æ¿ô¼Ò½Ì ½ÃÀå Çü¼º¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀ» ÁÖµµÇÏ´Â °¡Àå Áß¿äÇÑ ±â¼ú Çõ½Å Áß Çϳª´Â ÷´Ü ºÐ¼® Àåºñ¿Í °í󸮷® ½ºÅ©¸®´× ±â¼úÀÇ Ã¤ÅÃÀÔ´Ï´Ù. ¾×ü Å©·Î¸¶Åä±×·¡ÇÇ Áú·® ºÐ¼®(LC-MS) ¹× ÇÙ Àڱ⠰ø¸í(NMR) ºÐ±¤¹ý°ú °°Àº ÀÌ·¯ÇÑ ±â±â´Â ´õ ³ôÀº Á¤È®µµ¿Í ´õ ºü¸¥ ºÐ¼® ½Ã°£À» Á¦°øÇÏ¿© CRO°¡ ´ë·®ÀÇ »ùÇÃÀ» ºü¸£°í Á¤È®ÇÏ°Ô Ã³¸®ÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº º¹ÀâÇÑ ºÐÀÚ¿Í ºÒ¼ø¹°À» ½Äº°Çϰí Á¤·®ÈÇÏ´Â µ¥ ƯÈ÷ Áß¿äÇϸç, ÀǾàǰ °Ë»ç¿¡ ¾ø¾î¼´Â ¾È µÉ Çʼö ¿ä¼Ò·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù. ±â±â ¿Ü¿¡µµ ÀÚµ¿È ¹× ·Îº¿ °øÇÐÀº ½ÇÇè½Ç ¿öÅ©Ç÷ο쿡 Çõ¸íÀ» ÀÏÀ¸ÄÑ È¿À²¼ºÀ» ³ôÀ̰í ÀÎÀû ¿À·ùÀÇ °¡´É¼ºÀ» ÁÙ¿´½À´Ï´Ù. ÀÚµ¿È ½Ã½ºÅÛÀº »ùÇà Á¶Á¦, µ¥ÀÌÅÍ ¼öÁý ¹× ºÐ¼®°ú °°Àº ´ë·® ¹Ýº¹ ÀÛ¾÷À» °ü¸®Çϰí ÀϰüµÇ°í ¹Ýº¹ °¡´ÉÇÑ °á°ú¸¦ º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù. À̴ ƯÈ÷ °í󸮷® ½ºÅ©¸®´×À̳ª ¾ÈÁ¤¼º Å×½ºÆ®¿Í °°ÀÌ ¼öõ °³ÀÇ »ùÇÃÀ» µ¿½Ã¿¡ ó¸®ÇØ¾ß ÇÏ´Â ºÐ¾ß¿¡¼ ƯÈ÷ À¯¿ëÇÕ´Ï´Ù. ¶ÇÇÑ, Ŭ¶ó¿ìµå ÄÄÇ»ÆÃ°ú µ¥ÀÌÅÍ ºÐ¼®ÀÇ ÅëÇÕÀ» ÅëÇØ Á¦¾à»ç¿Í CRO´Â µ¥ÀÌÅ͸¦ º¸´Ù È¿À²ÀûÀ¸·Î ÀúÀå, °øÀ¯ ¹× ºÐ¼®ÇÒ ¼ö ÀÖ°Ô µÇ¾úÀ¸¸ç, Àü ¼¼°è ÆÀ °£ÀÇ Çù¾÷À» °£¼ÒÈÇÏ°í µ¥ÀÌÅÍ ¹«°á¼º ±ÔÁ¤À» ÁؼöÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.
ÀǾàǰ ºÐ¼® ½ÃÇè ¾Æ¿ô¼Ò½ÌÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ½ÃÀå µ¿ÇâÀº ¹«¾ùÀΰ¡?
Á¦¾à ºÐ¼® ½ÃÇè ¾Æ¿ô¼Ò½ÌÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¸î °¡Áö ÁÖ¿ä ½ÃÀå µ¿ÇâÀÌ ÀÖ½À´Ï´Ù. »ý¹°ÇÐÀû Á¦Á¦¿Í ¹ÙÀÌ¿À½Ã¹Ð·¯¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼ °í±Þ ºÐ¼® Å×½ºÆ® ¼ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. »ý¹°ÇÐÀû Á¦Á¦´Â ±âÁ¸ ÀúºÐÀÚ ÀǾàǰº¸´Ù Å©±â°¡ Å©°í º¹ÀâÇϱ⠶§¹®¿¡ ǰÁú, À¯È¿¼º ¹× ¾ÈÀü¼ºÀ» º¸ÀåÇϱâ À§ÇØ ´õ ¾ö°ÝÇϰí Àü¹®ÀûÀÎ Å×½ºÆ® ÇÁ·ÎÅäÄÝÀÌ ÇÊ¿äÇÕ´Ï´Ù. »ý¹°ÇÐÀû ºÐ¼® ½ÃÇè¿¡ ´ëÇÑ Àü¹®¼ºÀ» °®Ãá CRO´Â ƯÈ÷ »ý¹°ÇÐÀû Á¦Á¦¿¡ ´ëÇÑ ±ÔÁ¦ ¿ä°ÇÀÌ ¾ö°ÝÇØÁü¿¡ µû¶ó ÀÌ·¯ÇÑ Ä¡·á¹ýÀ» °³¹ßÇÏ´Â Á¦¾àȸ»ç¿¡ ÇʼöÀûÀÎ ÆÄÆ®³Ê°¡ µÇ°í ÀÖ½À´Ï´Ù. ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¶Ç ´Ù¸¥ ÁÖ¿ä Æ®·»µå´Â ÀǾàǰ °³¹ß¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ °¨½Ã°¡ °ÈµÇ°í ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ¹Ì±¹ ½ÄǰÀǾ౹(FDA)°ú À¯·´ÀǾàǰû(EMA)°ú °°Àº ±ÔÁ¦ ±â°üÀº ÀǾàǰÀÇ ¾ÈÀü¼º, ǰÁú, À¯È¿¼º¿¡ ´ëÇÑ °¡À̵å¶óÀÎÀ» °ÈÇϰí ÀÖÀ¸¸ç, Á¦¾à»çµéÀº ±ÔÁ¦ Áؼö ¹× °íǰÁú ½ÃÇè¿¡ ´ëÇÑ Àü¹®¼ºÀ» Á¦°øÇÒ ¼ö ÀÖ´Â CRO¸¦ ã°í ÀÖ½À´Ï´Ù. ¿©±â¿¡´Â ºÒ¼ø¹°, ¾ÈÁ¤¼º, ¿È ½ÃÇè, Á¦Á¶ °øÁ¤ÀÌ ¿ì¼öÀǾàǰ Á¦Á¶°ü¸®±âÁØ(GMP)À» ÁؼöÇÏ´ÂÁö È®ÀÎÇÏ´Â °Í µîÀÌ Æ÷ÇԵ˴ϴÙ. Ư¼ö ÀǾàǰ°ú ¸ÂÃãÇü ÀǾàǰÀÇ º¸±Þµµ º¸´Ù Àü¹®ÀûÀÎ ½ÃÇè ¼ºñ½ºÀÇ Çʿ伺À» ³ôÀ̰í ÀÖ½À´Ï´Ù. ¸ÂÃã Ä¡·á, ƯÈ÷ À¯ÀüÇÐ ¹× Èñ±ÍÁúȯ¿¡ ±â¹ÝÇÑ Ä¡·á´Â ¸Å¿ì Ư¼öÇÑ ºÐ¼®¹ýÀÌ ÇÊ¿äÇÑ °æ¿ì°¡ ¸¹Àºµ¥, ¸¹Àº Á¦¾à»ç°¡ À̸¦ ÀÚüÀûÀ¸·Î ¼öÇàÇÒ ¼ö ÀÖ´Â ¿ª·®À» °®ÃßÁö ¸øÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó Á¦¾à»çµéÀº Á¦¾à °³¹ßÀÇ Æ´»õ ºÐ¾ß¿¡ Æ¯ÈµÈ CRO¿¡ °Ë»ç ¼ö¿ä¸¦ ¾Æ¿ô¼Ò½ÌÇÏ´Â °æ¿ì°¡ ´Ã°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¦¾àȸ»ç°¡ ÀǾàǰ °³¹ß¿¡¸¸ ÁýÁßÇÏ°í ´Ù¸¥ ¸ðµç ±â´ÉÀ» ¾Æ¿ô¼Ò½ÌÇÏ´Â ¹öÃß¾ó ÆÄ¸¶(Virtual Pharma) ¸ðµ¨·ÎÀÇ ÀüȯÀº Á¾ÇÕÀûÀÎ ºÐ¼® Å×½ºÆ® ¼ºñ½º¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í °¡¼ÓȽÃ۰í ÀÖ½À´Ï´Ù.
ÀǾàǰ ºÐ¼® ½ÃÇè ¾Æ¿ô¼Ò½Ì ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎ
Á¦¾à ºÐ¼® ½ÃÇè ¾Æ¿ô¼Ò½Ì ½ÃÀåÀÇ ¼ºÀå¿¡´Â ¸î °¡Áö ¿äÀÎÀÌ ÀÖÀ¸¸ç, °¢ ¿äÀÎÀº ¿ÜºÎ ¼ºñ½º Á¦°ø¾÷ü¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ³ôÀÌ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ¿äÀÎ Áß Çϳª´Â ƯÈ÷ »ý¹°ÇÐÀû Á¦Á¦ ¹× ¹ÙÀÌ¿À½Ã¹Ð·¯ ÀǾàǰ ºÐ¾ß¿¡¼ ÀǾàǰ ºÐÀÚ°¡ Á¡Á¡ ´õ º¹ÀâÇØÁö°í ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÀǾàǰÀº ¾ÈÀü¼º, ¼øµµ ¹× È¿´ÉÀ» º¸ÀåÇϱâ À§ÇØ º¸´Ù Á¤±³ÇÑ ºÐ¼® Å×½ºÆ® ¹æ¹ýÀÌ ÇÊ¿äÇϸç, Á¦¾àȸ»ç°¡ ³»ºÎÀûÀ¸·Î ºÎÁ·ÇÑ °íµµ·Î Àü¹®ÈµÈ Àåºñ¿Í Àü¹®Áö½ÄÀ» »ç¿ëÇØ¾ß ÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ÀÌ¿¡ µû¶ó º¹ÀâÇÑ »ý¹°ÇÐÀû Á¦Á¦ ½ÃÇèÀ» ó¸®ÇÒ ¼ö ÀÖ´Â ±â¼ú·Â°ú ±ÔÁ¦Àû ³ëÇϿ츦 °®Ãá CRO¿¡ ÀÌ·¯ÇÑ ¾÷¹«¸¦ ¾Æ¿ô¼Ò½ÌÇÏ´Â ¿òÁ÷ÀÓÀÌ È°¹ßÇØÁö°í ÀÖ½À´Ï´Ù. ¾Æ¿ô¼Ò½ÌÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¶Ç ´Ù¸¥ Áß¿äÇÑ ¿ä¼Ò´Â ¾Æ¿ô¼Ò½ÌÀÌ Á¦¾àȸ»ç¿¡ °¡Á®´ÙÁÖ´Â ºñ¿ë Àý°¨ °¡´É¼ºÀÔ´Ï´Ù. ºÐ¼® ½ÃÇèÀ» ¾Æ¿ô¼Ò½ÌÇÔÀ¸·Î½á ±â¾÷Àº °í°¡ÀÇ Àåºñ¿Í ÀÎÇÁ¶ó¿¡ ´ëÇÑ ¸·´ëÇÑ ÀÚº» ÅõÀÚ¸¦ ÇÇÇÒ ¼ö ÀÖ°í, »ç³» ¿¬±¸¼ÒÀÇ Àη ¹èÄ¡ ¹× À¯Áö¿Í °ü·ÃµÈ ºñ¿ëµµ Àý°¨ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ´Â ÀÚüÀûÀ¸·Î ½ÃÇè ¿ª·®À» °³¹ßÇÒ ÀÚ¿øÀÌ ¾øÁö¸¸ ½Å¾à Èĺ¸ ¹°ÁúÀ» °³¹ßÇϱâ À§ÇØ °íǰÁú ºÐ¼® ¼ºñ½º¸¦ ÀÌ¿ëÇØ¾ß ÇÏ´Â ¼Ò±Ô¸ð ¹ÙÀÌ¿ÀÅ×Å© ±â¾÷À̳ª ½Å»ý ±â¾÷¿¡°Ô ƯÈ÷ ¸Å·ÂÀûÀÔ´Ï´Ù. Á¦¾àȸ»çµéÀÌ Àü ¼¼°è ±ÔÁ¦ ´ç±¹ÀÇ Á¡Á¡ ´õ ±î´Ù·Î¿öÁö´Â ¿ä±¸»çÇ׿¡ Á÷¸éÇϰí Àֱ⠶§¹®¿¡ ±ÔÁ¦ ´ç±¹ÀÇ ¾Ð·Âµµ ¾Æ¿ô¼Ò½Ì¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. Á¦¾à ÄÄÇöóÀ̾𽺿¡ Á¤ÅëÇÑ CRO´Â ½ÃÇè ÇÁ·Î¼¼½º°¡ ¼¼°è Ç¥ÁØ¿¡ ºÎÇÕÇϵµ·Ï º¸ÀåÇÏ°í ½ÂÀÎ °úÁ¤¿¡¼ Áö¿¬ ¹× °ÅºÎ À§ÇèÀ» ÁÙÀÓÀ¸·Î½á ºÐ¸íÇÑ ÀÌÁ¡À» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ÀǾàǰ °³¹ßÀÇ ¼¼°èÈ Ãß¼¼´Â Á¦¾à»ç°¡ ¿©·¯ Áö¿ª¿¡ °ÉÃÄ ¿î¿µµÇ´Â °ÍÀ» ÀǹÌÇϸç, °¢ Áö¿ª¸¶´Ù °íÀ¯ÇÑ ±ÔÁ¦ ¿ä°ÇÀÌ Á¸ÀçÇÑ´Ù´Â °ÍÀ» ÀǹÌÇÕ´Ï´Ù. µû¶ó¼ ¼¼°è »ç¾÷ Àü°³¿Í º¹ÀâÇÑ ±ÔÁ¦ ȯ°æÀ» ±Øº¹ÇÒ ¼ö ÀÖ´Â ´É·ÂÀ» °®Ãá CRO¿¡ ´ëÇÑ ÀÇÁ¸µµ°¡ ´õ¿í ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î, µðÁöÅÐ ±â¼ú°ú µ¥ÀÌÅÍ ºÐ¼®ÀÇ ±Þ¼ÓÇÑ ¹ßÀüÀ¸·Î ÀÎÇØ R&D ÇÁ·Î¼¼½º¸¦ ÃÖÀûÈÇϰíÀÚ ÇÏ´Â Á¦¾à»ç¿¡°Ô ¾Æ¿ô¼Ò½ÌÀº ¸Å·ÂÀûÀÎ ¼±ÅÃÀÌ µÇ°í ÀÖ½À´Ï´Ù. CRO´Â °í±Þ µ¥ÀÌÅÍ ºÐ¼® ¿ª·®À» Á¦°øÇÔÀ¸·Î½á ½ÃÇè °á°ú¿¡ ´ëÇÑ ±íÀº ÀλçÀÌÆ®¸¦ Á¦°øÇϰí, ÀÇ»ç°áÁ¤À» °¡¼ÓÈÇϸç, Àüü ÀǾàǰ °³¹ßÀÇ È¿À²¼ºÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεé°ú °³ÀÎȵǰí Àü¹®ÈµÈ ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ¸Â¹°¸®¸é¼ ÀǾàǰ ºÐ¼® ½ÃÇè ¾Æ¿ô¼Ò½Ì ½ÃÀåÀº ¾ÕÀ¸·Îµµ °·ÂÇÑ ¼ºÀå¼¼¸¦ À̾ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
Global Pharmaceutical Analytical Testing Outsourcing Market to Reach US$16.3 Billion by 2030
The global market for Pharmaceutical Analytical Testing Outsourcing estimated at US$10.3 Billion in the year 2023, is expected to reach US$16.3 Billion by 2030, growing at a CAGR of 6.8% over the analysis period 2023-2030. Bioanalytical Testing Service, one of the segments analyzed in the report, is expected to record a 8.0% CAGR and reach US$6.4 Billion by the end of the analysis period. Growth in the Method Development & Validation Service segment is estimated at 6.8% CAGR over the analysis period.
The U.S. Market is Estimated at US$2.8 Billion While China is Forecast to Grow at 6.2% CAGR
The Pharmaceutical Analytical Testing Outsourcing market in the U.S. is estimated at US$2.8 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 6.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.5% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.3% CAGR.
Global Pharmaceutical Analytical Testing Outsourcing Market – Key Trends & Drivers Summarized
How Has the Pharmaceutical Analytical Testing Outsourcing Industry Evolved Over Time?
The pharmaceutical analytical testing outsourcing industry has undergone a profound evolution over the past two decades, primarily driven by the increasing complexity of drug development, regulatory scrutiny, and the need for cost efficiencies. Traditionally, pharmaceutical companies conducted most of their analytical testing in-house, managing all stages of drug development from research to market entry. However, as drug pipelines have grown more complex and regulatory demands have increased, many companies have begun outsourcing these specialized testing functions to external partners. This shift allows pharmaceutical companies to focus on their core competencies, such as drug discovery and commercialization, while leveraging the expertise of contract research organizations (CROs) for analytical testing services.
Today, outsourcing has become a vital component of pharmaceutical research and development (R&D). Pharmaceutical analytical testing encompasses a wide range of services including raw material testing, method development, stability testing, bioanalytical services, and product release testing. Outsourcing these services has allowed pharmaceutical companies to access state-of-the-art technology, advanced instrumentation, and regulatory expertise without the need for significant capital investment. As a result, the outsourcing market has grown exponentially, with CROs offering a comprehensive suite of services to meet the demands of both small biotech firms and large pharmaceutical companies alike.
How Are Technological Advancements Shaping the Pharmaceutical Analytical Testing Outsourcing Market?
Technological advancements are playing a critical role in shaping the pharmaceutical analytical testing outsourcing market by improving the accuracy, efficiency, and speed of testing processes. One of the most significant innovations driving this market is the adoption of advanced analytical instruments and high-throughput screening technologies. These instruments, such as liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance (NMR) spectroscopy, offer higher precision and faster analysis times, enabling CROs to handle large volumes of samples quickly and accurately. These technologies are particularly important for the identification and quantification of complex molecules and impurities, making them indispensable in pharmaceutical testing. In addition to instrumentation, automation and robotics have revolutionized laboratory workflows, allowing for greater efficiency and reducing the chances of human error. Automated systems can manage large volumes of repetitive tasks such as sample preparation, data collection, and analysis, ensuring consistent and reproducible results. This has become particularly valuable in areas like high-throughput screening and stability testing, where thousands of samples may need to be processed simultaneously. Additionally, the integration of cloud computing and data analytics has enabled pharmaceutical companies and CROs to store, share, and analyze data more efficiently, streamlining collaboration across global teams and ensuring compliance with data integrity regulations.
What Are the Key Market Trends Driving Outsourcing in Pharmaceutical Analytical Testing?
Several key market trends are driving the growth of outsourcing in pharmaceutical analytical testing. The increasing focus on biologics and biosimilars has significantly impacted the demand for advanced analytical testing services. Biologics, which are larger and more complex than traditional small-molecule drugs, require more rigorous and specialized testing protocols to ensure quality, efficacy, and safety. CROs with expertise in bioanalytical testing are becoming essential partners for pharmaceutical companies developing these therapies, especially as regulatory requirements for biologics become more stringent. Another major trend influencing the market is the rising regulatory scrutiny in drug development. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are enforcing stricter guidelines on drug safety, quality, and efficacy, prompting pharmaceutical companies to seek out CROs that can provide expertise in regulatory compliance and high-quality testing. This includes testing for impurities, stability, and degradation, as well as ensuring that manufacturing processes adhere to Good Manufacturing Practices (GMP). The increasing prevalence of specialty and personalized medicines is also driving the need for more specialized testing services. Personalized therapies, particularly those based on genetics or rare diseases, often require highly specific analytical methods, which many pharmaceutical companies may not have the in-house capability to perform. As a result, these companies are increasingly outsourcing their testing needs to CROs that specialize in niche areas of drug development. Additionally, the shift toward virtual pharma models, where companies focus exclusively on drug development and outsource all other functions, has further accelerated the demand for comprehensive analytical testing services.
Key Factors Fueling the Growth of the Pharmaceutical Analytical Testing Outsourcing Market
The growth in the pharmaceutical analytical testing outsourcing market is driven by several factors, each contributing to the increasing reliance on external service providers. One of the key drivers is the rising complexity of drug molecules, particularly in the biologics and biosimilars sector. These drugs require more sophisticated analytical testing methods to ensure their safety, purity, and efficacy, which often necessitates the use of highly specialized equipment and expertise that pharmaceutical companies may lack internally. This has prompted the outsourcing of these tasks to CROs that possess the technological capabilities and regulatory know-how to handle complex biologics testing. Another critical factor fueling growth is the cost-saving potential that outsourcing offers pharmaceutical companies. By outsourcing analytical testing, companies can avoid significant capital investment in expensive equipment and infrastructure while also reducing the costs associated with staffing and maintaining in-house laboratories. This is especially appealing to smaller biotech firms or start-ups that may lack the resources to develop in-house testing capabilities but require access to high-quality analytical services to advance their drug candidates. Regulatory pressures are also driving the demand for outsourcing, as pharmaceutical companies face increasingly stringent requirements from regulatory agencies worldwide. CROs with expertise in regulatory compliance offer a distinct advantage by ensuring that testing processes meet global standards, mitigating the risk of delays or rejections during the approval process. Additionally, the growing trend toward globalization in drug development means that pharmaceutical companies are working across multiple geographic regions, each with its own regulatory requirements. This further increases the reliance on CROs that have a global footprint and the ability to navigate complex regulatory landscapes. Lastly, the rapid advancements in digital technologies and data analytics have made outsourcing an attractive option for pharmaceutical companies looking to optimize their R&D processes. CROs that offer advanced data analytics capabilities can provide deeper insights into testing results, accelerating decision-making and improving the overall efficiency of drug development. These factors, combined with the growing demand for personalized and specialized medicines, ensure that the pharmaceutical analytical testing outsourcing market will continue to experience robust growth in the years to come.
Select Competitors (Total 42 Featured) -